🇺🇸 FDA
Pipeline program

GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

CLEE011O12301C

Phase 3 small_molecule active

Quick answer

GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE for hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC). is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials